thymosin beta 4 and bpc 157 BPC-157 + TB-500: Tissue Regeneration Research Thymosin Alpha & Beta and

Antoniou SA, Mller-Stich BP, Antoniou GA, et al

Djezzar, J

Song W, Song G, Zhao C, Li X, Pei X, Zhao W, et al

increasingly used for moderate-to-severe CD Antibiotics: Metronidazole, ciprofloxacin for perianal disease, fistulae, abscesses Coding Impact of Biologic Therapy When a patient is receiving biologic therapy for Crohns disease, coders should verify: HCPCS code for the specific biologic agent (J1745, J3357, J3380, J7999) is separately reported for the infusion encounter Infusion administration code (CPT 96413, 96415) is reported with the biologic J-code Long-term use of immunosuppressants should be captured with Z79.899 (long-term use of other medication) when relevant Biologic use combined with Crohns disease supports HCC 35 mapping and higher risk scores When corticosteroid use (prednisone, budesonide) extends beyond 90 days, assign Z79.52 (long-term use of systemic steroids)